2991 completed, 714 terminated, 672 recruiting, 443 unknown. 5581 Phase 1, 1833 Phase 2.
Follow Skin and Connective Tissue Diseases: new trials by email Literature Review of Skin and Connective Tissue Diseases trials Research Report on Skin and Connective Tissue Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabichromene Safety in Rheumatoid Arthritis Cannabichromene - Arthritis, Rheumatoid | Phase 1 / Phase 2 | Withdrawn | Crystal Lederhos Smith | 2028-07-15 | 2026-09-23 | |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus | Phase 1 | Withdrawn | Caribou Biosciences, Inc. | 2027-12-01 | 2025-09-19 | |
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| Multi-4SCAR-T Therapy Targeting Breast Cancer 4SCAR T cells - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-06-01 | 2026-11-02 |
| Placental Cells for Diabetic Foot Ulcers Placenta Stem Cells - Diabetic Foot Ulcer | Phase 1 | Not yet recruiting | Wake Forest University Health Sciences | 12 | 2027-03-01 | 2026-10-23 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis | Phase 1 | Not yet recruiting | AbelZeta Inc. | 12 | 2027-03-01 | 2026-10-13 |
| Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 6 | 2027-01-31 | 2026-09-09 |
| Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB rAAV9-CMV-hNAGLUop - Sanfilippo Syndrome (MPS III) | Phase 1 / Phase 2 | Not yet recruiting | NeuroGT | 9 | 2027-01-18 | 2026-09-14 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| HEALTH Trial - Healthy Adult Evaluation of Ivermectin Bioequivalence: Infant Versus Standard Formulation ivermectin infant formula preparation, Standard ivermectin 3mg tablet - Scabies | Phase 1 | Suspended | Murdoch Childrens Research Institute | 52 | 2027-01-01 | 2026-10-09 |
| Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases Trastuzumab Deruxtecan, Stereotactic Radiosurgery - Breast Cancer, HER2-positive Breast Cancer | Phase 1 | Not yet recruiting | Baptist Health South Florida | 20 | 2027-01-01 | 2026-10-01 |
| Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. BLEX 404 Oral Liquid - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | BioLite, Inc. | 44 | 2027-01-01 | 2026-04-13 |
| Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) Bone marrow-derived mesenchymal stromal cells (MSCs) - Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III | Phase 1 / Phase 2 | Not yet recruiting | Emory University | 12 | 2027-01-01 | 2026-05-08 |
| Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 18 | 2027-01-01 | 2026-09-09 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| HER2 Vaccine for Locally Advanced Breast Cancer HER2 Vaccine - Breast Cancer, HER2-positive Breast Cancer | Phase 1 | Recruiting | Pravin T.P Kaumaya | 36 | 2027-01-01 | 2026-11-05 |
| Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | Shenzhen MagicRNA Biotechnology Co., Ltd | 12 | 2026-12-31 | 2026-08-12 |
| Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy Biospecimen Collection, Internet-Based Intervention, Medical Device Usage and Evaluation - Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Not yet recruiting | City of Hope Medical Center | 8 | 2026-12-23 | 2026-06-05 |
| A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer GDC-4198, Fulvestrant, Letrozole - Advanced or Metastatic Breast Cancer | Phase 1 | Not yet recruiting | Genentech, Inc. | 165 | 2026-12-15 | 2026-11-05 |
Showing 20 of 5581. Sign in to see all of them.
Breast Neoplasms (1876) · Melanoma (1215) · Carcinoma, Non-Small-Cell Lung (536) · Triple Negative Breast Neoplasms (463) · Ovarian Neoplasms (411) · Arthritis, Rheumatoid (384) · Neoplasm Metastasis (351) · Neoplasms (345) · Colorectal Neoplasms (344) · Lupus Erythematosus, Systemic (286) · Stomach Neoplasms (261) · Pancreatic Neoplasms (254) · Carcinoma, Renal Cell (242) · Lung Neoplasms (240) · Squamous Cell Carcinoma of Head and Neck (231)
Skin Diseases (4783) · Neoplasms by Site (3305) · Neoplasms (3046) · Breast Diseases (2190) · Neoplasms by Histologic Type (1701) · Neoplasms, Nerve Tissue (1286) · Neuroectodermal Tumors (1285) · Neoplasms, Germ Cell and Embryonal (1284) · Immune System Diseases (1237) · Neuroendocrine Tumors (1236) · Nevi and Melanomas (1224) · Skin Neoplasms (1200) · Connective Tissue Diseases (984) · Urogenital Diseases (937)
pembrolizumab (267) · Cyclophosphamide (222) · Paclitaxel (168) · Nivolumab (145) · Trastuzumab (142) · Ipilimumab (111) · Fulvestrant (97) · fludarabine (97) · Carboplatin (89) · Capecitabine (84) · Docetaxel (75) · Interleukin-2 (66) · aldesleukin (64) · palbociclib (58) · Letrozole (54)
National Cancer Institute (NCI) (182) · Pfizer (121) · GlaxoSmithKline (103) · Novartis Pharmaceuticals (92) · M.D. Anderson Cancer Center (87) · AstraZeneca (67) · Bristol-Myers Squibb (59) · Eli Lilly and Company (55) · Memorial Sloan Kettering Cancer Center (54) · Hoffmann-La Roche (53) · Amgen (44) · Mayo Clinic (41) · Merck Sharp & Dohme LLC (37) · National Institute of Allergy and Infectious Diseases (NIAID) (36) · H. Lee Moffitt Cancer Center and Research Institute (35)
United States (3216) · China (635) · Spain (398) · Australia (361) · United Kingdom (350) · Canada (325) · France (324) · Germany (324) · South Korea (211) · Italy (190) · Belgium (181) · Japan (179) · Netherlands (162) · Taiwan (108) · Poland (104)
PMID 34628605, PMID 34741731, PMID 36648215, PMID 24577748, PMID 25749867, PMID 30627694, PMID 31401903, PMID 32379297, PMID 32747469, PMID 33011075, PMID 35642432, PMID 40443562, PMID 12473512, PMID 16157940, PMID 16546506, PMID 16758122, PMID 16783576, PMID 17273752, PMID 17906897, PMID 18245541, PMID 18392824, PMID 18536917, PMID 18726994, PMID 19351776, PMID 20113933, PMID 20845479, PMID 21332269, PMID 21730275, PMID 21989902, PMID 22256804, PMID 22547151, PMID 24765228, PMID 24983357, PMID 25006719, PMID 25144817, PMID 25421091, PMID 25482871, PMID 25837513, PMID 26138472, PMID 26290435, PMID 27099766, PMID 27112532, PMID 27484900, PMID 28143815, PMID 28925994, PMID 29526614, PMID 29776017, PMID 29976218, PMID 31215818, PMID 31527168
2023 (69), 2015 (49), 2016 (44), 2017 (42), 2018 (42), 2019 (41), 2025 (39), 2014 (36), 2009 (26), P30CA016672 (16), U01CA062490 (15), UM1CA186709 (15), P30CA015083 (14), 2008 (13), P30CA033572 (12)